Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01266642 · ClinicalTrials.gov registry record · Phase 2
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
A Phase 2 study of Invasive Breast Carcinoma and Stage II Breast Cancer AJCC v6 and v7, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 301
- Enrollment target
- 7
- Study locations
NCT01266642 is a Phase 2 study of Invasive Breast Carcinoma and Stage II Breast Cancer AJCC v6 and v7 that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 301 participants, below the 478-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (37% lower). The trial reports 7 study locations across 3 states.
The verdict
NCT01266642, a Phase 2 study of Invasive Breast Carcinoma and Stage II Breast Cancer AJCC v6 and v7, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 301 participants
- Enrollment target
- 7
- Study locations
Study Summary
This randomized phase II trial studies how well hypofractionated radiation therapy (RT) works compared to standard RT in treating patients with ductal breast carcinoma in situ (DCIS) or early invasive breast cancer. Radiation therapy (RT) uses high energy x-rays to kill tumor cells. Giving higher doses of RT over a shorter period of time may kill more tumor cells and have fewer side effects. It is not yet known if hypofractionated RT is more effective than standard RT in treating breast cancer.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- RADIATION External Beam Radiation Therapy
- OTHER Laboratory Biomarker Analysis
- RADIATION Hypofractionated Radiation Therapy
Study Locations (7)
Texas
- MD Anderson in The Woodlands - Conroe
- M D Anderson Cancer Center - Houston
- MD Anderson West Houston - Houston
- MD Anderson League City - League City
- MD Anderson in Sugar Land - Sugar Land
Arizona
- Banner MD Anderson Cancer Center - Gilbert
Florida
- UF Cancer Center at Orlando Health - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2011-02-08 |
| Est. Completion | 2040-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01266642
The ClinicalTrials.gov registry entry for NCT01266642 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 478-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (37% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Invasive Breast Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT01266642 reports 7 study locations spanning 3 distinct geographic areas - top geographies include Texas, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT01266642 about?
NCT01266642 is a clinical study titled "Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer". This randomized phase II trial studies how well hypofractionated radiation therapy (RT) works compared to standard RT in treating patients with ductal breast carcinoma in situ (DCIS) or early invasive breast cancer. Radiation therapy (RT) uses high energy x-rays to kill tumor cells. Giving higher do...
What is the current status of trial NCT01266642?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 301 participants. The study started on 2011-02-08. Estimated completion is 2040-11-30.
What conditions does trial NCT01266642 study?
This clinical trial studies the following conditions: Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Ductal Breast Carcinoma in Situ, Stage IB Breast Cancer AJCC v7.
What interventions are being tested in trial NCT01266642?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), External Beam Radiation Therapy (RADIATION), Laboratory Biomarker Analysis (OTHER), Hypofractionated Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT01266642?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01266642 being conducted?
This trial has 7 study locations across Arizona, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
RECRUITING · Phase 2
-
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Metformin and Nightly Fasting in Women With Early Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Invasive Breast Carcinoma
All registered trials for this condition
Stage II Breast Cancer AJCC v6 and v7
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.